Atherosclerosis, a condition characterized by plaque buildup in the arteries, poses a significant threat to cardiovascular health. Current therapies often focus on managing symptoms rather than addressing the underlying cause. BELACT offers a unique approach by targeting the very building blocks of atherosclerotic plaques.
BELACT, a biotechnologically produced enzyme, works by breaking down both hyaluronic acid and sulfated glycosaminoglycans, two key components of the extracellular matrix found in plaques. This targeted action helps reduce plaque volume without damaging the surrounding vascular structure, allowing natural repair mechanisms to take effect.
Unlike existing treatments that may stabilize or bypass deposits, BELACT actively reduces them. By eliminating pathological ECM components, blood vessels can regain their natural flexibility and function. Its recombinant production ensures a sustainable and GMP compliant supply, avoiding animal derived components.
Preclinical and clinical studies demonstrate the safety and efficacy of BELACT. In vitro tests show significantly higher specific activity compared to traditional animal hyaluronidase preparations. With its unique mechanism of action and potential for scalability, BELACT offers a promising new avenue for treating atherosclerosis.